Exosomes vs PDRN: What US Clinics Should Know Before Adding Either

Exosomes and PDRN keep appearing in the same sentence, usually in the same slide deck, and almost always as if they were two flavours of the same thing. They are not. One is a class of cell-derived vesicle with no standardised composition; the other is a family of DNA fragments from a specific source. Lumping them together is convenient for marketing and dangerous for procurement.

For a US clinic or distributor, the more important difference is not biological. It is regulatory. The two categories sit in completely different places in how they are classified, what can legally be claimed about them, and what documentation a supplier should be able to produce before you put either into a treatment room.

This guide is written for clinic owners, medical directors and buyers who are being sold both and need to tell them apart. It sets out what each actually is, how the US regulatory picture differs, why claims create more risk than ingredients, what the published evidence does and does not support, and the eight questions to ask a supplier before introducing either.

One note on scope. Nothing here is legal advice, and nothing here is a statement about any specific company's products. Regulatory positions in this area are unsettled and change. Where a question is genuinely open, this article says so rather than inventing certainty — the operating rule for any clinic should be to confirm the current position with FDA's published guidance and with counsel before introducing a product.

If you are still working out how the two are positioned commercially, our comparison of PDRN serum versus exosome serum covers the marketing framing; this article is about the part the marketing leaves out.

What Each One Actually Is

The two categories differ in origin, composition and — critically — in how much of their contents anyone can specify.

PDRN: fragments, not cells

PDRN stands for polydeoxyribonucleotide: short DNA fragments, most commonly derived from salmon testis, with a defined molecular weight range and a defined source. That definition matters, because it means a supplier can describe the material in terms of origin, fragment size distribution, purity and concentration.

How the material is extracted and purified — and whether the process is validated and documented — is where most of the real quality difference sits, which is why PDRN extraction, sourcing and quality control is worth understanding before comparing prices.

Exosomes: vesicles, not a single molecule

"Exosome" describes a size class of extracellular vesicle — roughly 30 to 150 nanometres — released by cells. What an exosome product contains depends entirely on which cells produced it, how they were cultured, how the vesicles were isolated, and how the final material was preserved.

That is the core problem. Two products both labelled "exosomes" can differ in cargo, purity, contaminating protein, and the presence or absence of intact vesicles, and neither label has to tell you which of those you are getting. An exosome product is not a substance with a specification in the way PDRN can be; it is a manufacturing process with a label attached.

Why the comparison is lopsided

Comparing "PDRN versus exosomes" is therefore not like comparing two fillers. It is closer to comparing a defined chemical ingredient with a category of biological material. That asymmetry runs through everything below: evidence, regulatory classification, and what a supplier can actually warrant.

The US Regulatory Picture

This is the section that decides whether the rest of the comparison matters. A product's biology does not determine its legal status; its intended use and the claims made for it do.

How a product gets classified

In the US, a product intended to treat, cure, mitigate or prevent disease, or intended to affect the structure or function of the body, is generally regulated as a drug or biological product and requires premarket approval or licensure before it can be marketed for that use. A product marketed only to cleanse, beautify or alter appearance, with no therapeutic claim, may fall under cosmetics — a different regime with different obligations.

The pivotal variable is the intended use, which is established largely by what the seller says and implies: on the website, in the training deck, in the consent form, in the injector's script.

Where exosome products stand

FDA has publicly communicated that exosome products promoted for therapeutic use are generally subject to regulation as drugs or biological products, and that such products require the applicable premarket authorisation before they may be marketed for those uses. As of this writing we are not aware of an FDA-approved exosome product for aesthetic injection; clinics should verify the current position rather than rely on this article.

The practical consequence is uncomfortable for buyers: a product being widely sold, widely used and widely discussed does not make it authorised. Market presence is not a regulatory status.

Where PDRN products stand

PDRN is not a single regulated entity; it is a material, and its status depends on the finished product and its claims. A topical cosmetic containing PDRN, an injectable sold for skin quality, and a product sold to treat a condition are three different regulatory propositions even if the raw material is identical.

For a clinic, the question is therefore never "is PDRN legal?" but "what exactly is this product, how is it presented, and what claims are being made for it in my market?"

What "not approved" means in practice

• It does not necessarily mean the product is adulterated or that its use is a criminal act by the clinician.

• It does mean the product has not been through a premarket review of safety and effectiveness for that intended use.

• It means the seller's claims determine exposure, and those claims are usually written by the seller, not the clinic.

• It means insurance cover, adverse-event reporting and product liability all become questions to answer before, not after.

Safety expectations around injectable risk — infection, hypersensitivity, granuloma, vascular compromise — do not disappear because a product's legal status is unresolved. If anything, the absence of a premarket review removes the layer of independent scrutiny that would normally catch problems early, which is why our review of reported PDRN side effects and clinical considerations focuses on what to monitor rather than what to promise.

Claims Are Where Clinics Get Into Trouble

The cosmetic/drug line

The same vial can be a cosmetic or a drug depending on the sentence next to it. "Improves the appearance of skin" sits on one side. "Repairs tissue", "reduces inflammation", "stimulates collagen production" and anything describing a mechanism of action in the body generally sit on the other.

Most clinics do not write these sentences; they inherit them from supplier decks and repost them on social media. That is still the clinic's exposure, because the clinic is the one making the claim to the patient.

Three claims that create risk

First, mechanism claims: naming a pathway (autophagy, cell signalling, receptor activation) turns a cosmetic presentation into a therapeutic one. Second, comparator claims: "works better than filler", "replaces PRP" — these imply clinical superiority that the evidence does not support. Third, outcome claims with numbers: "92% of patients saw improvement" without a citable, product-specific study is a liability, not a marketing asset.

A simple internal test: if a sentence would need a clinical trial to be true, it belongs in a regulatory dossier, not on an Instagram post.

Where the claim crosses into a safety statement — "safe for all skin types", "no downtime", "suitable for everyone" — the risk shifts from regulatory to clinical, which is a separate problem covered in our comparison of safety profiles across skin booster categories.

Evidence: What Is Actually Published

PDRN: a real but narrow literature

PDRN has a published literature going back years, concentrated in wound healing, tissue repair and skin quality. Much of it is small, single-centre, and conducted with formulations that may not match what is on the market today. That does not make it worthless; it means the evidence supports cautious, limited claims rather than broad ones.

The honest summary is that the direction of the signal is plausible and the strength of the evidence is modest. Our review of what current evidence says about PDRN separates topical from injectable data, because those are routinely conflated in marketing.

Exosomes: promising research, thin clinical base

The exosome literature is large and growing, but it is dominated by in-vitro work, animal models, and studies of exosomes from specific cell sources in specific disease contexts. Human aesthetic use — injected, serial, in healthy patients — is not supported by the kind of controlled data that would justify the claims commonly made.

There is also a definitional problem in the literature itself: studies rarely characterise the vesicle preparation to a standard that would let you map a published result onto a commercial product.

Reading the literature without overreading it

Three questions sort most of it: was the study in humans, was the product characterised, and was the endpoint clinical or mechanistic? A paper showing a signalling change in cultured fibroblasts is a legitimate contribution and a weak basis for a treatment menu.

When a supplier cites a study, four checks separate a real citation from a decoration. Who carried it out and whether they disclosed funding; whether the product studied is the product being sold, at the same characterisation; whether the endpoint was clinical or mechanistic; and how long patients were followed after the final session.

A fifth check catches most of the rest: how many patients. A case series of six is a legitimate early signal and a weak basis for a claim about "most patients". Suppliers rarely misquote the percentage; they omit the denominator.

What to Ask a Supplier Before You Introduce Either

The eight questions below are the ones that separate a professional supplier from a box-shifter. Ask them in writing and keep the answers in the product file.

1. What exactly is in the vial — source, characterisation, and how the material is standardised batch to batch?

2. What is the regulatory status of this specific product in the US, and under what classification is it being sold?

3. What claims are permitted for it, in writing, and which claims must the clinic avoid?

4. Does it have a documented sterility assurance process, and what are the endotoxin results?

5. Which batch release tests are performed, and can I see a certificate of analysis for the lot I receive?

6. What adverse events have been reported, and what is the supplier's protocol for investigating one?

7. What happens if a batch is implicated in a reaction — recall, credit, or investigation?

8. What documentation will the clinic receive to support its own due diligence and insurance position?

A supplier who cannot answer questions 2 and 3 in writing is asking the clinic to absorb a regulatory risk it did not create. That is not a reason to walk away from a category; it is a reason to walk away from a supplier.

Product literacy helps here. Knowing how HA, PDRN, PN and peptide formulations differ in composition and handling makes the answers to question 1 much easier to evaluate.

Cost Structure: Where the Money Actually Goes

Per-treatment consumable cost

Consumable cost for either category is usually a minority of the treatment price. The larger variables are practitioner time, room time, and the cost of managing a patient who does not get the result the marketing promised. Exosome products tend to carry a higher per-vial cost and, in many markets, a much higher regulatory uncertainty cost — which does not appear in the invoice but shows up in legal review, insurance questions and consent documentation.

Pricing and repeat logic

Both categories are sold on repeat treatment. That is a legitimate business model and also a warning sign: when a product's revenue depends on serial sessions, the marketing tends to migrate toward claims that justify them. Compare the repeat interval you can defend clinically with the one the supplier's price list assumes.

If the treatment plan involves a topical component alongside injections, the economics differ again, and our comparison of injectable versus topical PDRN sets out where the cost and the effect actually land.

Three Misjudgements That Repeat

The first is treating them as substitutes. They are not interchangeable in composition, regulation or evidence base, so a decision to use one should not be justified by the other's popularity.

The second is letting marketing copy stand in for regulatory analysis. A polished brand, a conference booth and a supplier's confident assertion that "it's fine in the US" are not a legal position. The clinic needs a written answer it can file.

The third is conflating research heat with clinical evidence. A field can be scientifically exciting and clinically unproven at the same time — those are not contradictory statements, and buyers who treat them as one tend to overpay for uncertainty.

A useful discipline is to write down, for each product on the menu, the single sentence the clinic would defend in front of a regulator, an insurer and a patient who had a bad outcome. If those three sentences differ, the claims are ahead of the evidence and need to be pulled back before the next campaign.

How to Read a Supplier's Regulatory Answer

Suppliers in this category give roughly four kinds of answer about US status. Three of them sound reassuring and none of them is a legal position.

An acceptable answer has three properties: it is specific to the product rather than the category, it is in writing, and it distinguishes what the supplier asserts from what a regulator has determined. Anything vaguer is a marketing answer to a legal question.

It also helps to ask the same question twice, once in the sales conversation and once in an email to the technical contact. Divergence between the two is itself information.

If You Already Offer One of Them

Most clinics reading this are not starting from zero. They have a product in the fridge and a treatment menu that already mentions it. The useful exercise is a short retrospective audit rather than a decision to stop or continue.

Start with the claims. Pull every page, post, price list and consent form that references the product and mark each sentence that describes what happens inside the body, compares it to another treatment, or quantifies an outcome. Those are the sentences that define intended use and they are usually the ones nobody reviewed.

Then check the product file. For each batch in stock, is there a certificate of analysis, a sterility statement and an endotoxin result? If a patient reacted tomorrow, could the clinic produce the lot number, the supplier's adverse event contact and the documentation sent with the shipment within an hour?

Then check the consent and insurance position. Does the consent form describe the product accurately, including the fact that it has not been through premarket review if that is the case? Has the clinic's insurer been told what is being injected? These are the two places where an otherwise defensible practice turns into an uninsured one.

Finally, record the outcome of the audit with a date. A documented review is worth more than a good intention, both to a regulator and to a plaintiff's lawyer.

Conclusion: Decide With the Paperwork, Not the Deck

Exosomes and PDRN are not two versions of the same product. One is a defined material with a modest evidence base; the other is a category of biological material whose US regulatory position is unresolved and whose clinical evidence for aesthetic injection is thin.

For a clinic, the decision is less about biology than about documentation: what the product is, how it is classified, what may be claimed, and what happens when something goes wrong. A supplier who can answer those four questions in writing is worth a premium. One who cannot is a liability with a marketing budget.

The safe operating rule is unglamorous — verify the current FDA position, keep claims inside what the evidence supports, document every batch, and treat "everyone is using it" as evidence about the market rather than about the product.

AOWITA supplies PDRN and hyaluronic acid formulations with batch documentation for professional buyers, and will discuss the documentation package before any commercial discussion. The complete guide to PDRN for skin covers indications and treatment planning, and the high-purity salmon PDRN HA serum page lists the current specification.